New Study Highlights Underuse of Brachytherapy Boost in Prostate Cancer Treatment

A new analysis published in Brachytherapy reveals a significant and ongoing gap between clinical evidence and real-world practice for men with intermediate – and high-risk prostate cancer.

Despite strong Level 1 evidence and national guideline support, brachytherapy boost (EBRT-BT) remains underutilized. Using data from the SEER national database, the study found that only 13.9% of eligible men received EBRT-BT between 2015 and 2020—even though this approach has been shown to improve biochemical progression-free survival.

These findings underscore the continued need for awareness, education, and access to brachytherapy as a highly effective treatment option.

Theragenics congratulates the study authors for their important contribution to advancing the understanding and adoption of evidence-based prostate cancer treatment.